Dirucotide (MBP8298) / Eli Lilly, Medwell Capital Corp - LARVOL DELTA

Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression. (PubMed, Mult Scler J Exp Transl Clin) - "SPMS participants (n = 485) enrolled in a 2-year placebo-controlled (negative) trial assessing the efficacy of MBP8298 were classified as progressors if a 6-month sustained increase in Expanded Disability Status Scale (EDSS) (≥1.0 or ≥0.5 for a baseline of ≤5.5 or ≥6.0 respectively) was observed...SPMS disability progression was best predicted by non-parametric ML. If confirmed, ML could select those with highest progression risk for inclusion in SPMS trial cohorts and reduce the number of low-risk individuals exposed to experimental therapies."

Journal

Deep learning of baseline brain lesion masks better predicts SPMS progression than baseline clinical, demographic and MRI measures (ECTRIMS 2019) - " Participants from a 2-year placebo-controlled (negative) SPMS trial assessing MBP8298 were categorized as progressors if there was 6-month sustained increase in EDSS (≥1.0 and ≥0.5 for baseline ≤5.5 and ≥6.0 respectively)... Using only lesion masks, DL was able to learn features more predictive of disability progression in SPMS than user-defined features. Observed improvements in precision and NPV of deep-learned features compared to user-defined features may be due to the DLN learning use of spatial information that is lost in global BPF and T2LV measures."

Clinical

Effect of different doses of gadolinium contrast agent on clinical outcomes in MS. (PubMed, Mult Scler J Exp Transl Clin) - "...Outcomes from a cohort of 612 secondary progressive MS (SPMS) patients, enrolled in a two-year, placebo-controlled (negative) trial assessing the efficacy of MBP8298, were acquired...There were no significant differences in any of the outcomes between the two cohorts. There were no differences in the disability progression measures between the two cohorts, indicating that gadolinium does not result in greater clinical worsening in SPMS after a two-year period."

Clinical • Clinical data • Journal